Home > News > BioSante Pharmaceuticals Initiates Phase III Study of LibiGel®
December 28th, 2006
BioSante Pharmaceuticals Initiates Phase III Study of LibiGel®
Abstract:
BioSante Pharmaceuticals, Inc. (Amex: BPA) announced today that it has initiated a Phase III safety and efficacy trial of LibiGel® (transdermal testosterone gel) in the treatment of female sexual dysfunction (FSD). The double-blind, placebo-controlled Phase III trial will enroll approximately 360 surgically menopausal women for a six-month clinical trial, conducted under a Phase III protocol and investigational new drug application (IND) reviewed by and on file with the U.S. Food and Drug Administration (FDA).
Source:
businesswire.com
Bookmark:
Announcements
Pioneering breakthrough of chemical nanoengineering to design drugs controlled by light June 18th, 2013
Study Shows How the Nanog Protein Promotes Growth of Head and Neck Cancer June 18th, 2013
New Method to Synthesize Zinc Oxide Nanoparticles with High Catalytic Activity June 18th, 2013
Production of Polyaniline Biosensors Modified with Conductive Polymer Composites June 18th, 2013
Human Interest/Art
Yes, nanoscience can enhance humans – but ethical guidelines must be agreed: People 'enhanced' into spider-climbing individuals with hugely projected breasts and Einstein-brains… Where will it stop? June 5th, 2013
Heinrich Rohrer dies at 79; a father of nanotechnology: With IBM colleague Gerd Binnig, Rohrer invented the scanning tunneling microscope, which can show individual atoms on a surface and move them around May 23rd, 2013
Oh, Christmas tree, oh Christmas tree: A nano end for Christmas tree needles January 2nd, 2013
INIC Inks MoU to Apply Nanotechnology in Iran's Carpet Industry December 18th, 2012